Jcr Pharmaceuticals Sustainability Profile
JCR Pharmaceuticals Co., Ltd., commonly referred to as JCR Pharma, is a leading biopharmaceutical company headquartered in Japan. Established in 2003, the company has made significant strides in the development of innovative therapies, particularly in the fields of rare diseases and regenerative medicine. With a strong focus on enzyme replacement therapies and gene therapies, JCR Pharma is renowned for its unique products that address unmet medical needs. The company operates primarily in Japan, with expanding influence in international markets. Notable achievements include the successful launch of its flagship products, which have positioned JCR Pharma as a key player in the biopharmaceutical industry. Through its commitment to research and development, JCR Pharmaceuticals continues to enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Jcr Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jcr Pharmaceuticals's score of 56 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jcr Pharmaceuticals's reported carbon emissions
In 2024, JCR Pharmaceuticals reported total carbon emissions of approximately 65,000,000 kg CO2e, comprising 2,779,000 kg CO2e from Scope 1, 8,392,000 kg CO2e from Scope 2, and a significant 57,014,000 kg CO2e from Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, including all relevant scopes. In 2023, the company recorded total emissions of about 14,255,621,000 kg CO2e, with Scope 1 emissions at 28,439,000 kg CO2e and Scope 2 emissions at 46,552,000 kg CO2e. The Scope 3 emissions were notably high, reaching approximately 14,255,621,000 kg CO2e, indicating a substantial impact from upstream and downstream activities. JCR Pharmaceuticals has set near-term climate commitments, aiming for net-zero emissions in Scope 1 and Scope 2 by 2025. The company is actively working to assess and disclose climate-related risks in line with TCFD recommendations and is focused on calculating greenhouse gas emissions across its entire supply chain. The emissions data is not cascaded from any parent organization, ensuring that JCR Pharmaceuticals' reporting reflects its own operational impact. The company continues to enhance its sustainability initiatives, demonstrating a commitment to reducing its carbon footprint and addressing climate change effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 32,573,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 49,959,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000,000 | 00,000,000 |
How Carbon Intensive is Jcr Pharmaceuticals's Industry?
How Carbon Intensive is Jcr Pharmaceuticals's Location?
Jcr Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jcr Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
